Aclara Biosciences (NASDAQ:ACLA)
Historical Stock Chart
From Jun 2019 to Jun 2024
John Weinstein, M.D. Ph.D. Appointed to ACLARA Scientific Advisory Board
Prominent NCI Cancer Expert Added to Advisory Board
MOUNTAIN VIEW, Calif., Dec. 11 /PRNewswire-FirstCall/ -- ACLARA BioSciences
announced that John N. Weinstein, M.D. Ph.D. of Bethesda, MD has been appointed
to its Scientific Advisory Board. Dr. Weinstein's research focus is the
molecular pharmacology of cancer cells utilizing techniques such as gene
expression profiling and bioinformatics, and the identification and
characterization of new agents for the treatment of cancer. ACLARA's advisory
board now comprises five internationally-renowned scientists and physicians with
interests covering both basic research and clinical treatment of a range of
different cancers and immune system disorders.
"We are particularly pleased to have a prominent scientist such as Dr. Weinstein
join the advisory board as he is actively involved in fundamental cancer
research. The application of eTag(TM) assays to the clinical evaluation of
potential cancer drugs is emerging as a very exciting opportunity, and we look
forward to Dr. Weinstein's advice and counsel as we commercialize this
application," commented Thomas Klopack, ACLARA chief executive officer.
ACLARA's eTag assays enable pharmaceutical researchers and physicians involved
in clinical trials to test patient samples and identify subtle but important
protein differences among patients. This information facilitates the
identification of those patients most likely to respond to a particular
pharmaceutical compound or treatment regimen, based on the disease mechanisms
detected at the molecular and cellular level.
About ACLARA
ACLARA BioSciences, Inc. is commercializing its proprietary eTag Assay System
for drug discovery research and to support preclinical and clinical development
of specific targeted therapies. The eTag Assay System is a high performance,
high throughput system for the simultaneous measurement of 10's to 100's of
genes, proteins, and cell-based antigens across thousands of samples. The eTag
platform makes it possible for researchers to measure multiple aspects of a
complex biological system, enabling the study of gene expression, protein
expression, cell signaling and pathway activation, protein-protein interaction,
post-translational modifications and cell receptor binding -- all in the same
sample and with the same platform. The system uses ACLARA's proprietary eTag
reporters to multiplex the analysis of genes and/or proteins. Specific
molecular binding events result in the release of electrophoretically distinct
eTag reporters, which are then resolved by standard capillary electrophoresis to
provide precise, sensitive quantitation of multiple analytes -- directly from
cell lysates of cultured or primary cells, as well as fresh and fixed tissue
samples. More information on ACLARA can be obtained on the Company's web site
at http://www.aclara.com/.
Forward Looking Statement
All statements in this news release that are not historical are forward-looking
statements within the meaning of the Securities Exchange Act of 1934 as amended.
Such forward-looking statements are subject to factors that could cause actual
results to differ materially for ACLARA from those projected. Those factors
include risks and uncertainties relating to the performance of the Company's
products, product development, development and commercialization efforts,
successful establishment of and performance under collaborative and commercial
agreements, adoption of its technologies by pharmaceutical and biotechnology
companies, the validity and enforceability of patents, the possible infringement
of the intellectual property of others, technological approaches of ACLARA and
its competitors, and other risk factors identified in the Company's Form 10-K
for the year ended December 31, 2002 and Form 10-Q for the quarter ended
September 30, 2003 as filed with the Securities and Exchange Commission.
Trademarks
ACLARA BioSciences is a registered trademark, and eTag and the ACLARA logo are
trademarks of ACLARA BioSciences, Inc.
DATASOURCE: ACLARA BioSciences, Inc.
CONTACT: Alfred Merriweather, VP, Finance and CFO of ACLARA,
+1-650-210-1200, or
Web site: http://www.aclara.com/